In addition to Wegovy, incretin mimetics FDA-approved for chronic weight management include Saxenda (liraglutide), also made by Novo Nordisk, and Zepbound (tirzepatide), produced by Fortune 500 ...
In addition to Wegovy, incretin mimetics FDA-approved for chronic weight management include Saxenda (liraglutide), also made by Novo Nordisk, and Zepbound (tirzepatide ... View this interactive chart ...
People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why
Several patients using brand-name drugs like Ozempic, Wegovy, Mounjaro, and Zepbound experienced problems ... Novo Nordisk is of the opinion that the benefit-risk profile of semaglutide remains ...
Wegovy’s label was updated last year to reflect its ability to reduce the risk of cardiovascular events like heart attacks and strokes, while Zepbound’s label now includes treatment for ...
The pharmaceutical giant markets the drug as Wegovy for people with obesity ... in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next ...
Global Healthy Living Foundation Says Hims & Hers Health Super Bowl ad omits safety risks and side effects of its weight loss ...
His colleagues’ use of Wegovy and Zepbound reminds him of the use of statins, drugs that lower cholesterol, in their early days. Cardiologists, who were most familiar with the consequences of ...
Zepbound, another weight-loss drug, was taken off the compounding list in December after manufacturer Eli Lilly increased production. The same is expected to happen soon for Wegovy, which is made ...
Vision issues are rare but usually permanent Researchers point to the popularity of drugs as cause for concern Previous medications linked to vision issues have had label changes Vision issues are ...
After telehealth brand Hims & Hers aired its first Super Bowl commercial Sunday night, competitor Novo Nordisk, which makes competing weight loss drugs Ozempic and Wegovy, responded with its own ...
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback